Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 195

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 195
---
 of 2023, the Company decided to streamline
its operations by terminating clinic services and suspending non-lead R&D projects. This measure is aimed at optimizing the allocation
of our resources and focusing our efforts on advancing our lead projects, which hold the most promise for commercial success and beneficial
impact. This decision aligns with our commitment to enhance shareholder value and effectively drive our core objectives forward in the
competitive landscape.

The following table summarizes our results of operations for the years
ended December 31, 2024, and 2023.

|                                                                          |     | Year Ended   
 December 31, 
 2024         |            |   |     | Year Ended   
 December 31, 
 2023         |             |   |
|:-------------------------------------------------------------------------|:----|:-------------|-----------:|:--|:----|:-------------|------------:|:--|
| Revenue                                                                  |     |              |            |   |     |              |             |   |
| Healthcare services income                                               |     | $            |          - |   |     | $            |     431,378 |   |
| Operating expenses                                                       |     |              |            |   |     |              |             |   |
| Cost of healthcare services                                              |     |              |          - |   |     |              |    (420,812 | ) |
| Research and development expenses                                        |     |              | (2,195,161 | ) |     |              |  (5,198,329 | ) |
| General and administrative fees                                          |     |              |   (669,486 | ) |     |              |  (1,930,637 | ) |
| Legal and professional fees                                              |     |              |   (803,285 | ) |     |              |  (2,538,161 | ) |
| Other operating expenses                                                 |     |              |   (272,609 | ) |     |              |  (1,067,690 | ) |
| Total expenses                                                           |     |              | (3,940,541 | ) |     |              | (11,155,629 | ) |
| Other (expense) income, net                                              |     |              |            |   |     |              |             |   |
| Loss on investments in marketable securities, net                        |     |              |          - |   |     |              |      (9,266 | ) |
| Unrealized gain from fair value change of the